D.E. Shaw & Co
PTLA

D.E. Shaw & Co’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

D.E. Shaw & Co’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-60,000
Closed -$2.08M – 3985
2019
Q1 		$2.08M Hold
60,000
– – ﹤0.01% 2136
2018
Q4 		$1.17M Buy
60,000
+40,000
+200% +$823K ﹤0.01% 2550
2018
Q3 		$533K Buy
+20,000
New +$653K ﹤0.01% 3076

Other funds holding PTLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

D.E. Shaw & Co's PTLA Position: Q2 2020 in Review

D.E. Shaw & Co sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 813,567 shares — an estimated $5.8M sold.

D.E. Shaw & Co first reported a position in PTLA in Q2 2013 and held it in 23 quarters. The position peaked at $66M in Q2 2017. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

  • D.E. Shaw & Co reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • D.E. Shaw & Co sold 813,567 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $5.8M.
  • D.E. Shaw & Co first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 23 quarters.
  • D.E. Shaw & Co's Portola Pharmaceuticals, Inc. position peaked at $66M in Q2 2017.
  • 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on D.E. Shaw & Co's 13F filing for Q2 2020, filed 14 Aug 2020.